2024-03-18 11:19:01
Hanmi Science (hereinfollowing referred to as Hanmi Group), a core business company, Hanmi Pharmaceutical, will participate in the ‘American Association for Cancer Research (AACR 2024)’ held in San Diego, USA from April 5 to 10 and reveal 10 new research projects, the largest number in the industry. It was announced on the 18th that it would do so.
Hanmi Pharmaceutical plans to unveil 10 new research projects at the AACR to be held in April.
A total of 10 research projects are being disclosed by Hanmi Pharmaceutical at this AACR: ▲p53-mRNA anticancer new drug ▲2 LAPSIL-2 analog (HM16390) ▲2 EZH1/2 dual inhibitor (HM97662) ▲selective HER2 exon 20 insertion mutation inhibitor ▲ Research results on IRE1α inhibitor (HM100168) ▲KRAS mRNA anti-cancer vaccine ▲YAP/TAZ-TEAD inhibitor, and ▲BH3120 based on the dual antibody platform (pentambody) being developed by Beijing Hanmi Pharmaceutical will be presented in a poster. .
A large number of researchers from Hanmi Pharmaceutical R&D Center will also attend to explain the contents of the poster presentation and introduce Hanmi’s innovation tasks.
First, Hanmi Pharmaceutical will announce the results of its research on the ‘next-generation p53-mRNA anti-cancer new drug’ targeting p53 mutant cancer using mRNA platform technology on the 7th. When mutations occur in the p53 protein, a representative tumor suppressor gene, cancer cells continuously divide and grow. Until now, attempts have been made to develop a treatment targeting p53 mutations, which occur at a high rate in cancer patients, but there is no commercially available drug, so Hanmi’s research is raising expectations.
In addition, the results of HM16390, a ‘next-generation interleukin-2 (IL-2) immunotherapy agent’ that has confirmed excellent anti-tumor efficacy in non-clinical studies, will be released on the 8th. HM16390 is a candidate material that optimizes the binding force between IL-2 receptors to provide strong anti-tumor efficacy as well as improved safety, and is expected to show therapeutic efficacy in various cancer types, including melanoma and colon cancer, as well as kidney cancer and pancreatic adenocarcinoma. .
In addition, we will also present research results on HM97662, a ‘next-generation EZH1/2 dual inhibitor’ that is expected to overcome the resistance mechanism of selective EZH2 inhibitors. This conference presents the possibility that it can be used as a new treatment option for solid tumors with mutations in protein complexes (SWI/SNF such as ARID1A).
The research results of ‘Selective HER2 Exon 20 Insertion Mutation Inhibitor’ and ‘IRE1α Inhibitor (HM100168)’, which are new anti-cancer pipelines that have not been disclosed until now, will also be revealed on the 8th, and the R&D center of Beijing Hanmi Pharmaceutical, a Chinese subsidiary of Hanmi Group, will take the lead. The research results of BH3120, a next-generation immunotherapy drug under development, will be announced on the 9th. This nonclinical study contains results demonstrating the anticancer synergy effect and safety profile of BH3120 in combination with PD-1 inhibitors in addition to monotherapy.
An mRNA-based anticancer vaccine targeting major KRAS mutation antigens, which Hanmi Pharmaceutical first unveiled at last year’s AACR, and a new small molecule inhibitor that binds to the palmitate pocket of the transcription factor TEAD and selectively inhibits the YAP/TAZ-TEAD interaction. Research results will be announced on the 9th and 10th, respectively.
Choi In-young, head of Hanmi Pharmaceutical’s R&D Center, said, “This year’s AACR announcement has a special meaning in that it further solidifies our position as the ‘leading edge in new drug development’ by introducing a large number of ‘next-generation new drugs’ that will continue Hanmi’s R&D innovation on the overseas stage.” He added, “mRNA-based “We will present new possibilities for innovation that go beyond existing approaches, such as treatments, and show that we are leading the development of new drugs using various modalities that will change the cancer treatment paradigm based on Korea and the United States’ unrivaled R&D capabilities,” he said.
Hanmi Group President Lim Joo-hyun (Hanmi Science Strategic Planning Director) said, “New drug development is Hanmi’s DNA and a precious legacy that must be continued forever with unwavering will and philosophy.” He added, “Pharmaceutical companies without new drug development are dead companies.” “We will focus more on R&D to firmly maintain our philosophy and values.”
1710764596
#Hanmi #Pharmaceutical #announces #research #projects #AACR.. #industry
